Detta meddelande gladde investerarna 
BIOHIT and Restalyst announce collaboration to improve non-invasive early gastric cancer detection
Biohit Oyj Press release 6 February 2025 at 11.00 am local time (EEST)
BIOHIT Oyj, a pioneer in non-invasive diagnostics for gastrointestinal diseases, has signed a letter of intent (LOI) to collaborate with Singapore-headquartered Restalyst to deliver transformative solutions for early gastric cancer detection.
The EU reported approximately 135,600 cases of gastric cancer and 95,400 deaths in 2022, with late-stage diagnosis contributing significantly to the high mortality rate.1 The strategic alignment of BIOHIT and Restalyst underscores their shared commitment to advancing non-invasive gastric cancer risk stratification for early detection.
The parties will collaborate among other things on distribution of their technologies, expanding their reach to a broader customer base through their respective networks.
Jussi Hahtela, CEO of BIOHIT OYJ, commented: “BIOHIT is proud to join forces with Restalyst. Gastric cancer remains a critical global health challenge, and, by collaboration, we can provide clinicians tools that enable early gastric cancer detection. This partnership not only reinforces our commitment to offer global solutions to global health care challenges but also positions us to expand our reach and impact in the field of gastrointestinal diagnostics.”
Zaccheus Peh, CEO of Restalyst, added: “We are very pleased to be entering into this collaboration with BIOHIT. It comes at a time when Restalyst is preparing for a pivotal moment in the company’s journey, one that will enhance our ability to grow and deliver greater value to our stakeholders. Building on this momentum, we are excited to collaborate with BIOHIT to bring innovative, non-invasive solutions for early gastric cancer detection to a wider audience. This partnership represents a significant step towards improving patient outcomes and addressing a critical global health need.”